

BAUSCH + LOMB PHARMACEUTICAL RETINA PORTFOLIO

Explore these products to help you manage patients in your practice

The Bausch + Lomb Pharmaceutical Retina Portfolio is available to help you meet your patients' therapeutic needs. We know you have many choices when it comes to treating your patients.

Personalized patient assistance programs are available from Bausch + Lomb for these treatment options.

INDICATION AND IMPORTANT SAFETY INFORMATION

RETISERT®

RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

Exhibit 2158

Page 01 of 02

<https://www.bauschretinarx.com>

Samsung v. Regeneron
IPR2023-00442
U.S. Pat. 10,130,681
Exhibit 2158

[Click here](#) for additional Important Safety Information for RETISERT®

VISUDYNE®

VISUDYNE® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

VISUDYNE® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.

[Click here](#) for additional Important Safety Information for VISUDYNE®

BAUSCH+LOMB

[Legal Notice](#) | [Privacy Policy](#) | [Contact Us](#)

VISUDYNE is a trademark of Novartis AG used under license. © 2020 Bausch & Lomb Incorporated or its affiliates. All rights reserved. VID.0048.USA.20

CALIFORNIA RESIDENTS: [DO NOT SELL MY PERSONAL INFORMATION](#)